Rafael Pharmaceuticals Announces Expansion into Israel of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer

    NEXT STORY
    Spring Bank Announces Research Agreement with The National Institute of Allergy and Infectious Diseases to Evaluate HBV Antisense Oligonucleotide Compounds
    PREV STORY
    Molecular Diagnostic Market To Reach USD 17.08 Billion By 2026 | Reports And Data
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Tetra Bio-Pharma’s Management Provides Corporate Update Ahead of Annual General Meeting

    author_avatar
    NASDAQ Market News

    UPS Partners With Matternet To Transport Medical Samples Via Drone Across Hospital System In Raleigh, N.C.

    author_avatar
    NASDAQ Market News

    Merus Announces Ono Pharmaceuticals Exercise of its Option for New Research and License Agreement to Generate Bispecific Antibody Targeting Autoimmune Diseases

    UTRECHT, The Netherlands, March 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology ...

    author_avatar
    NASDAQ Market News